Bigger than Dolly?
By Jesse Reynolds,
Genetic Crossroads
| 06. 29. 2007
Here in the United States, political maneuverings around embryonic stem cell research made headlines throughout June. But this was little more than rehearsed political theatre, reenacting a well-known script. The Democratic-controlled Congress once again passed a bill that would have undone restrictions on the federal funding of embryonic stem cell research, but the Republican President again vetoed it. Despite last year's electoral shift in Congress, the bill's advocates are still far short of the super-majority needed to override the veto.
Though the debate remains polarized and deadlocked, supporters of President Bush's restrictions - including many Republicans up for reelection next year - are no doubt looking for ways to extricate themselves from their increasingly unpopular position. To date, they've largely gambled on the emergence of alternative sources of stem cells that are just as powerful as those derived from embryos, but that can be produced without destroying embryos.
Until now, this strategy has been largely rhetorical. But it appears that scientific developments - including one that was heralded by several researchers as being as important as the birth of Dolly...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...